In a research report issued today, Maxim Group analyst Jason Kolbert reiterated a Buy rating on Achillion Pharmaceuticals (NASDAQ:ACHN) with a $22 price target, …
In a research report released Monday, Maxim Group analyst Jason Kolbert reiterated a Buy rating on Achillion Pharmaceuticals (NASDAQ:ACHN) with a $22 price …
Entry: $9.86 10/2/14 Take Profits: $14.
In a research report issued today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Achillion Pharmaceuticals (NASDAQ:ACHN) with a $22 price …
Investment Thesis We expect volatility in the share prices of HCV focused companies leading into this year’s AASLD meeting from November 7th to …
In a research note issued today, Maxim Group analyst Jason Kolbert reiterated a Buy rating and boosted his price target on Achillion Pharmaceuticals (ACHN) to …